Top Page
Aiml Resources
(AIML)
Aiml Resources (AIML) vs. S&P 500 (SPY)
Aiml Resources Business Overview & Revenue Model
Aiml Resources Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 600.14K | 466.01K | 65.41K | 0.00 | 0.00 | Gross Profit |
| 294.86K | -225.32K | 65.41K | 0.00 | 0.00 | EBIT |
| -1.66M | -1.35M | -3.35M | -1.43M | -195.03K | EBITDA |
| -1.66M | -1.30M | -3.42M | -1.43M | -176.56K | Net Income Common Stockholders |
| -3.28M | -1.42M | -3.17M | -2.73M | -235.91K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 216.86K | 14.56K | 525.24K | 3.49M | 177.17K | Total Assets |
| 329.69K | 1.51M | 2.04M | 3.59M | 319.87K | Total Debt |
| 197.72K | 809.37K | 261.34K | 320.29K | 422.00K | Net Debt |
| -3.73K | 804.84K | -213.73K | -3.05M | 284.25K | Total Liabilities |
| 1.54M | 1.79M | 1.55M | 1.51M | 2.14M | Stockholders Equity |
| -1.17M | -247.46K | 1.08M | 2.31M | -1.82M |
| Cash Flow | Free Cash Flow | |||
| -1.64M | -634.28K | -3.02M | -959.00K | -154.72K | Operating Cash Flow |
| -1.64M | -634.28K | -3.02M | -931.35K | -126.91K | Investing Cash Flow |
| -325.98K | -210.64K | -1.14M | -11.38K | -27.80K | Financing Cash Flow |
| 2.16M | 374.37K | 1.27M | 4.17M | 288.65K |
Aiml Resources Technical Analysis
Aiml Resources Peers Comparison
Aiml Resources Corporate Events
AI/ML Innovations Inc. has restructured its acquisition agreement with Quantum Sciences Ltd. to enhance capital efficiency and simplify its revenue structure. The revised terms include a reduction in consideration shares, nullification of previously agreed royalties, and a new revenue-sharing agreement. This restructuring aligns with AIML’s strategic focus on AI-powered health solutions, aiming to streamline operations and concentrate resources on high-growth areas, thereby improving flexibility for future investments and partnerships.
Spark’s Take on TSE:AIML Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIML is a Underperform.
The overall stock score for AIML is low due to significant financial instability, persistent losses, and negative cash flows. While technical analysis shows short-term upward momentum, the stock may be overbought. Valuation metrics are concerning with no dividend yield and a negative P/E ratio. However, recent corporate events indicate positive strategic initiatives that could improve future prospects.
To see Spark’s full report on TSE:AIML stock, click here.
AI/ML Innovations Inc. announced the departure of Tim Daniels from its Board of Directors, effective immediately. Daniels, who has been instrumental in guiding the company’s strategic direction and growth, will continue to support AIML in an advisory role. This change is part of AIML’s efforts to strengthen its leadership and advisory network to support its commercialization and strategic growth initiatives in AI-driven healthcare.
Spark’s Take on TSE:AIML Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIML is a Underperform.
The overall stock score for AIML is low due to significant financial instability, persistent losses, and negative cash flows. While technical analysis shows short-term upward momentum, the stock may be overbought. Valuation metrics are concerning with no dividend yield and a negative P/E ratio. However, recent corporate events indicate positive strategic initiatives that could improve future prospects.
To see Spark’s full report on TSE:AIML stock, click here.
AI/ML Innovations Inc. has appointed Jared Adelstein to its Board of Directors as part of its strategic growth and commercialization efforts in the AI-powered healthcare sector. This appointment is expected to enhance the company’s governance and leadership, supporting its mission to deliver innovative AI solutions in healthcare and marking a significant step in its growth trajectory.
Spark’s Take on TSE:AIML Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIML is a Underperform.
Aiml Resources faces considerable financial challenges, with persistent operational inefficiencies and negative earnings impacting its financial performance. While technical analysis suggests short-term upward momentum, the stock may be overbought. Valuation metrics are poor due to negative earnings, but recent corporate events suggest positive strategic shifts that could improve future outlook. Overall, the company’s financial instability significantly weighs down its stock score.
To see Spark’s full report on TSE:AIML stock, click here.
AI/ML Innovations Inc. has successfully closed an oversubscribed private placement, raising $2,165,900, surpassing its initial target of $2,000,000. The funds will be used for general working capital, and the strong investor participation reflects confidence in the company’s strategic direction. The company also announced modifications to existing warrants, adjusting the exercise price to $0.20, which aligns with its current financial strategies.
Spark’s Take on TSE:AIML Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIML is a Underperform.
AI/ML Innovations Inc. faces significant financial challenges with negative earnings and a highly leveraged balance sheet. While recent corporate actions indicate a strategic shift and attempts to improve financial health, the overall outlook remains cautious due to substantial operational inefficiencies and valuation concerns.
To see Spark’s full report on TSE:AIML stock, click here.
AI/ML Innovations Inc. announced a non-brokered private placement offering of up to 40 million units at $0.05 per unit, aiming to raise $2 million. The proceeds will be used for working capital, with each unit consisting of one common share and one warrant, exercisable into a common share at $0.15 over three years. The private placement is subject to necessary approvals, and finder’s fees will be paid to qualified finders.
AI/ML Innovations Inc. announced a proposed non-brokered private placement offering of up to 40,000,000 units at $0.05 per unit, aiming to raise up to $2,000,000. The proceeds will be used for working capital requirements, and the offering is subject to necessary approvals. This move is expected to bolster the company’s financial position and support its strategic initiatives in the AI and ML sectors.
AI/ML Innovations Inc. has announced its strategic exit from Tech2Heal, a France-based digital health company, to focus on the commercialization of its core holdings. This move allows AIML to realign its resources towards its primary subsidiaries, enhancing its market positioning in digital health innovations. The exit agreement involves relinquishing its equity position and board rights in Tech2Heal in exchange for the return of shares and equity, positioning AIML for future collaborations and growth in its core areas.
AI/ML Innovations Inc. has announced significant changes to its Board of Directors to align with its growth and commercialization goals. The appointment of Paul Duffy as Executive Chairman and Peter Kendall to the Board, along with the continued advisory roles of Mark Orsmond and Michael Nemirow, reflects the company’s strategic focus on enhancing its commercialization efforts and driving shareholder value.
AI/ML Innovations Inc. held its Annual General and Special Meeting virtually, where shareholders voted on several key resolutions. These included fixing the number of directors to four, re-electing directors Tim Daniels, Mark Orsmond, Michael Nemirow, and Drew Dundas, re-appointing Baker Tilly WM LLP as the company’s auditor, and approving the company’s Stock Option Plan and RSU/DSU Plan. The meeting’s outcomes are expected to solidify AIML’s governance structure and support its strategic focus on AI and ML-driven healthcare solutions.
AI/ML Innovations Inc. has announced key updates for its upcoming annual and special meeting, including the expansion of its board from three to four members. Dr. Drew Dundas, with extensive experience in technology and audiology, has been nominated to join the board, enhancing the company’s governance and expertise as it aims to accelerate its growth in AI-driven healthcare solutions.